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Objectives: Trypanosomabrucei drug transporters include the TbAT1/P2 aminopurine transporter and the high-af-
finity pentamidine transporter (HAPT1), but the genetic identity of HAPT1 is unknown. We recently reported that
loss of T. brucei aquaglyceroporin 2 (TbAQP2) caused melarsoprol/pentamidine cross-resistance (MPXR) in these
parasites and the current study aims to delineate the mechanism by which this occurs.
Methods: The TbAQP2 loci of isogenic pairs of drug-susceptible and MPXR strains of T. brucei subspecies were
sequenced. Drug susceptibility profiles of trypanosome strains were correlated with expression of mutated
TbAQP2 alleles. Pentamidine transport was studied in T. brucei subspecies expressing TbAQP2 variants.
Results: All MPXR strains examined contained TbAQP2 deletions or rearrangements, regardless of whether the
strains were originally adapted in vitro or in vivo to arsenicals or to pentamidine. The MPXR strains and AQP2 knock-
out strains had lost HAPT1 activity. Reintroduction of TbAQP2 in MPXR trypanosomes restored susceptibility to the
drugs and reinstated HAPT1 activity, but did not change the activity of TbAT1/P2. Expression of TbAQP2 sensitized
Leishmania mexicana promastigotes 40-fold to pentamidine and.1000-fold to melaminophenyl arsenicals and
induced a high-affinity pentamidine transport activity indistinguishable from HAPT1 by Km and inhibitor profile.
Grafting the TbAQP2 selectivity filter amino acid residues onto a chimeric allele of AQP2 and AQP3 partly restored
susceptibility to pentamidine and an arsenical.
Conclusions: TbAQP2 mediates high-affinity uptake of pentamidine and melaminophenyl arsenicals in trypano-
somes and TbAQP2 encodes the previously reported HAPT1 activity. This finding establishes TbAQP2 as an import-
ant drug transporter.
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Introduction
The protozoan parasite Trypanosoma brucei is the aetiological
agent of human African trypanosomiasis (HAT or sleeping sick-
ness). The subspecies T. b. gambiense and T. b. rhodesiense are re-
sponsible for West African and East African sleeping sickness,
respectively, and T. b. brucei is one of the pathogens that cause
animal African trypanosomiasis, a wasting disease of livestock.
Despite the recent introduction of nifurtimox/eflornithine combin-
ation therapy for the late, cerebral stage of HAT,1 there is an urgent
need for new drugs, driven in part by resistance to the diamidines,
phenanthridines and melaminophenyl arsenicals (MPAs) that
have been the central pillars of African trypanosomiasis treatment
for decades.2 An understanding of the mechanisms of resistance,
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and particularly of cross-resistance, is of great importance. Firstly,
molecular markers are required to study the epidemiologyof resist-
ance, particularly as phenotypic assessment in primary clinical/
veterinary isolates is impossible for many species of African tryp-
anosome and there is an unresolved debate about the extent of
treatment failure versus genuine resistance, especially with
respect to melarsoprol.3 Secondly, in the absence of new drugs
we need to make best use of the treatments available and, for
this, insight into resistance mechanisms and levels of cross-
resistance is essential. Importantly, new drug development must
take into account the resistance mechanisms to the current
drugs, in order to avoid cross-resistance.
Melarsoprol/pentamidine cross-resistance (MPXR) is a well-
known phenomenon in HAT and was first noted by Rollo and Wil-
liamson in 1951;4 although its causes have never been completely
resolved, it has long been clear this is linked to reduced drug accu-
mulation.5 – 7 The first drug transporter identified in trypanosomes
was the P2 adenosine/adenine transporter, which was initially
implicated in melarsoprol uptake8 and subsequently also in diami-
dine transport;9 – 11 the gene was designated TbAT1.12 All proto-
zoan nucleoside and nucleobase transporters identified to date
have been of the equilibrative nucleoside transporter family.13
Although the evidence of diamidine and arsenical transport by
TbAT1/P2 has become incontrovertible, it has become equally
clear that this transporter mediates only part of the uptake and
that this proportion is different for different diamidines in particu-
lar, as deletion of the TbAT1 gene led to a high level of resistance
to the veterinary diamidine diminazene aceturate14 and the
newer clinical candidates furamidine and CPD0801,15 but only to
a relatively minor loss of susceptibility to MPAs and pentami-
dine.14,16 Two additional, adenosine-insensitive pentamidine
transport activities were detected and functionally characterized
in T. b. brucei: a high-affinity pentamidine transporter (HAPT1)
and a low-affinity pentamidine transporter (LAPT1).17,18 HAPT1
was additionally found to be the secondary transporter for the ar-
senical drugs, with the loss of both the P2 and HAPT1 activities sim-
ultaneously leading to high-level MPXR.16,19Despite the HAPT1 and
LAPT1 activities having been first characterized over a decade
ago,17 the genes encoding these transporters remained unknown.
Recently, we reported that the aquaglyceroporin TbAQP2 con-
trols MPXR in T. b. brucei.20 Aquaporins (AQPs) are major intrinsic
proteins (MIPs) that are present in virtually every organism and
are commonly implicated in osmotic balance and, in the case of
aquaglyceroporins, in the bidirectional flux of some small, usually
uncharged solutes, such as glycerol and urea.21 AQPs have
attracted increasing pharmacological interest because of their im-
portant roles in many human physiological and pathophysiological
processes, including cancer, post-traumatic brain oedema, glau-
coma and epilepsy.22,23 Further pharmacological interest in AQPs
emerged when it became clear that these water channels can
also mediate the uptake of a wider array of molecules, including
some that are cytotoxic and display antimicrobial activity.24
Some AQPs, including LeishmaniamajorAQP1, transport antimony
and arsenic, most likely in the form of As(OH)3 and Sb(OH)3, which
structurally resemble glycerol.25,26 This has attracted much atten-
tion, because pentavalent antimonials such as Glucantime and
Pentostam, which are activated to a form of Sb(III), are a first-line
treatment for leishmaniasis.
T. brucei members of the AQP family are classified functional-
ly27,28 and phylogenetically29 as aquaglyceroporins. They are
closely related to LmAQP1 and human aquaglyceroporins, includ-
ing hAQP9, which reportedly allows the uptake of a wide variety of
uncharged solutes, including carbamides, polyols, purines and pyr-
imidines.30 The three T. b. brucei AQPs appear to have very similar
permeation patterns, mediating the uptake of glycerol, dihydroxy-
acetone, ribitol and urea.27 However, only TbAQP2 was implicated
in MPXR, with the re-expression of TbAQP3 in an aqp2/aqp3null line
having no effect on drug susceptibility.20
Here, we report that loss of the wild-type TbAQP2 open reading
frame (ORF) was observed in all MPXR strains (T. b. brucei,
T. b. gambiense and T. b. rhodesiense), whether they were selected
for resistance to MPAs or pentamidine, including strains selected in
vivo and able to be transmitted by tsetse flies. Based on our
detailed genetic, pharmacological and kinetic analysis, we con-
clude that TbAQP2 encodes the HAPT1 activity and that loss of
AQP2 function is sufficient and likely required for high-level MPXR.
Materials and methods
Trypanosome strains and culture
Bloodstream-formT. b. brucei, strain Lister 427 (s427; MiTat 1.2/BS221), and
its derivatives were maintained as previouslydescribed.16 Several derivative
lines were used: tbat12/2,14 B48,16 2T1,31 aqp2/aqp3 null strains32 and
P1000 cells (this paper). Procyclic-form T. b. gambiense STIB 386 wild-
type and Cymelarsan-resistant (386MR) lines, and T. b. bruceiSTIB 247 wild-
type and Cymelarsan-resistant (247MR) lines were grown as described
previously.33 The P1000 line was generated by further subculturing of
bloodstream forms of the B48 line in incrementally increasing concentra-
tions of pentamidine, starting at 75 nM, until the trypanosomes proliferated
in 1 mM pentamidine. This process took almost a year of continuous in vitro
adaptation (Figure S1a, available as Supplementary data at JAC Online),
which was presumably genetic in nature as the resistance phenotype has
proven to be completelystable even after storage in liquid nitrogen or trans-
formation to procyclic cells. There was no apparent in vitro growth defect
associated with the P1000 adaptations (Figure S1b, available as Supple-
mentary data at JACOnline). The STIB 900 line is T. b. rhodesiense, originally
isolated from a human patient in Tanzania, and was adapted in vitro for
resistance to pentamidine (STIB 900-P) or melarsoprol (STIB 900-M).34
Leishmania strains and culture
Leishmania mexicana promastigotes of strain MNYC/BZ/62/M37935 were
cultured in HOMEM medium (Invitrogen) supplemented with 10% fetal
bovine serum at 258C exactly as described for L. major promastigotes.36
Promastigotes were passed to fresh culture medium or used for analysis
when in mid-log culture.
Expression of aquaglyceroporins in T. b. brucei cell lines
AQP2 was expressed in the B48 and P1000 lines by modification of the ex-
pression vector pHD133637 to give pHDK21. This plasmid was digested with
NotI prior to transfection into trypanosomes. The pRPaiGFPx construct38 was
modified to express either the AQP2 or AQP2-3 chimera genes and was
digested with AscI prior to transfection. Primer sequences are given in
Table S1 (available as Supplementary data at JAC Online). The AQP3 and
AQP2-3 genes with their selectivity region altered to that of AQP220 were
synthesized by GenScript (New Jersey, USA) for insertion into pRPaiGFPx,38
to give N-terminally tagged proteins. The constructs were digested with
AscI prior to transfection. B48, P1000 or aqp2/aqp3 null strains were
washed in Human T Cell Nucleofector Solution for transfection using the ap-
propriate cassette with an Amaxa Nucleofector as described previously.39
Transfectants were grown and cloned out by limiting dilution in standard
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HMI-9/FBS containing the relevant antibiotic (5 mg/mL blasticidin for
pHDK21 and 2 mg/mL hygromycin for pRPaAQP2/pRPaAQP2-3).
Genome sequencing of STIB 900 lines
Whole genome sequencing of the three T. b. rhodesiense lines STIB 900,
STIB 900-M and STIB 900-P was carried out by 454 Life Sciences (Branford,
CT, USA) on the Genome Sequencer FLX Titanium, performing two shotgun
runs per line. All the high-quality reads were mapped to the reference
genome T. b. brucei 92740 from EBI-EMBL (version October 2011) using
SMALT (www.sanger.ac.uk/resources/software/smalt). Consensus se-
quence and variants were identified with SAMtools41 and inspected using
Artemis.42
Sequencing of AQP2 and AQP3 genes in drug-resistant
lines
TheAQP2andAQP3genes were sequenced from the drug-resistant lines as
well as from their respective wild-type lines. The genes were amplified from
genomic DNA using a proofreading polymerase and ligated into the pGEM-T
Easy subcloning vector and sequenced using standard procedures. The
primers used for amplification of the various genes are given in Table S1
(available as Supplementary data at JAC Online).
Cellular localization of chimeric AQP2/3
Localization of green fluorescent protein (GFP)-coupled chimeric AQP2/3
(GFP-chAQP2/3) and western blot with anti-GFP antiserum were performed
exactly as described for wild-type TbAQP2 and TbAQP3.20 Nuclear staining
was performed with 4′,6-diamidino-2-phenylindole (DAPI).
Transport assays
Transport assays with procyclic-43 and bloodstream-form trypano-
somes,44,45 and L. mexicana promastigotes,36,46 were performed as
described previously. Cultures were harvested at the mid-log growth
phase and washed into assay buffer (AB; 33 mM HEPES, 98 mM NaCl,
4.6 mM KCl, 0.55 mM CaCl2, 0.07 mM MgSO4, 5.8 mM NaH2PO4, 0.3 mM
MgCl2, 23 mM NaHCO3 and 14 mM glucose, pH 7.3) at a final concentration
of 108 cells/mL. Transport was initiated by the addition of 100 mL cells to
100 mL of a solution of the appropriate radiolabel in AB layered over oil
[7:1 dibutylphthalate/mineral oil (v/v); Sigma–Aldrich, St Louis, MO, USA]
and terminated by the addition of an ice-cold solution of 1 mL of unlabelled
permeant and immediate centrifugation through the oil layer. Radioactivity
in the cell pellet was determined by liquid scintillation counting and cor-
rected for non-specific association of radiolabel with the cells as described
previously.45 All experiments were performed in triplicate on at least three
independent occasions and analysed using the appropriate linear and non-
linear regression equations in GraphPad Prism 5.0. [3H]pentamidine
(3.26 TBq/mmol; product TRQ40084, batch 1) was custom synthesized by
Amersham using tritium gas, producing a general labelling of the pentami-
dine molecule.
Drug susceptibility assays
Drug susceptibilities of the bloodstream-form trypanosomes47 and L.mex-
icana promastigotes48 were determined using the Alamar blue assay
exactly as described previously, measuring fluorescence in 96-well plates
with a FLUOstar Optima (BMG Labtech, Durham, NC, USA) at wavelengths
of 544 nm for excitation and 620 nm for emission. EC50 values were calcu-
lated by non-linear regression using an equation for a sigmoidal dose–re-
sponse curve with variable slope (GraphPad Prism 5.0; GraphPad Software
Inc., San Diego, CA, USA).
Heterologous expression of T. brucei AQPs in Leishmania
promastigotes
TbAQP2 and TbAQP3 were amplified from genomic DNA by PCR using
Phusion polymerase (Thermo Scientific) and subcloned into the pNUS
vector for expression in Leishmania.49 The construct was verified bysequen-
cing before transfection into L. mexicana promastigotes using an Amaxa
Nucleofector (program U-33).
Results
Status of drug transporters and AQP2 in isogenic
susceptible/resistant trypanosome pairs
The study by Bakeret al.20 established a clear link between TbAQP2
and MPXR in the s427/B48 isogenic pair of T. b. brucei. The B48 line
was produced from the TbAT1-KO line (derived from s427 by tar-
geted deletion of TbAT1)14 followed by in vitro exposure to pent-
amidine.16 For TbAQP2 to be confirmed as a general genetic
marker for MPXR in trypanosomes, however, it is essential that
this link be upheld in further isogenic pairs showing MPXR, par-
ticularly where resistance has been induced (i) in vivo or (ii) to
the arsenical component rather than pentamidine and (iii) in
human-infective trypanosome subspecies. We thus widened our
investigations to the strains described in Table 1, which lists a
number of well-described isogenic strains with the desired charac-
teristics. These include strains of both human-infective subspecies,
T. b. gambiense and T. b. rhodesiense, in addition to the closely
related animal parasite T. b. brucei. The strains were adapted by
drug exposure in vivo or in vitro, by exposure to an MPA compound
(melarsoprol or Cymelarsan, its water-soluble derivative) or pent-
amidine. Some were shown to be transmissible by tsetse flies
and to mate in this vector.33 In all of these highly resistant
strains, theTbAT1/P2 transport activity is known to be deleted, non-
expressed or mutated (Table 1 and references therein) and it is
believed that this explains part, but crucially not all, of the resistant
phenotype.
The characterization of the isogenic pair s427/TbAT1-KO clearly
showed loss of P2 activity to be associated with only a minor loss of
susceptibility to pentamidine and MPAs, in addition to a much
higher degree of resistance to diminazene.14,50 Thus, high-level
MPXR is clearly a function of the loss of TbAT1 function in addition
to other mutation(s).51 We investigated MPXR in the T. b. brucei
247 and T. b. gambiense 386 isogenic pairs, both generated by in
vivo adaptation to Cymelarsan.33 Pentamidine cross-resistance
for T. b. brucei 247 was first reported by Scott et al.52 with
.50-fold pentamidine resistance in vivo for T. b. brucei247MR rela-
tive to its parental line and we confirm here that procyclic 247MR
were 74- and 755-fold resistant to pentamidine and Cymelarsan,
respectively; these numbers were 90- and 83-fold for 386MR
(Figure S2, available as Supplementary data at JAC Online).
Neither strain displayed resistance to phenylarsine oxide (PAO). As-
sessment of the HAPT1 and LAPT1 transporters in both isogenic
pairs confirmed that MPXR was associated with loss of HAPT1 activ-
ity: 247MR and 386MR did not express the activity whereas both
parental lines did. Figure S3 (available as Supplementary data at
JAC Online) illustrates this in detail for the 247 isogenic pair and
Table 2 summarizes the characterization of HAPT1 and LAPT1 of
the 247 and 386 isogenic lines.
We thus analysed the AQP2-AQP3 locus of the 247 and 386 iso-
genic pairs and discovered that the AQP2 gene was completely
T. brucei AQP2 is the HAPT1 pentamidine transporter
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absent from the 386MR line, whilst the AQP3 gene was identical to
that in the 386 wild-type line. In the 247MR line, however, a chimer-
ic gene of AQP2 and AQP3 had been formed in place of both wild-
type genes. This chimera is in-frame, producing a 939 bp ORF
composed of the first 363 bp of AQP2 and the last 576 bp of AQP3,
andisthusdifferentfromthechimerafoundinstrainB48(seebelow).
Detailed analysis of the AQP locus of the STIB 900 lines revealed
that both the pentamidine- and melarsoprol-resistant lines had
lost the AQP2 gene whilst retaining the AQP3 gene. The organiza-
tion of the AQP2-AQP3 locus in all the various strains so far exam-
ined is shown in Figure S4 (available as Supplementary data at JAC
Online). It appears that, in all cases, AQP2 is either lost completely
or recombined into a chimeric gene that encodes most of the resi-
dues comprising the AQP3 selectivity filter.
Expression of AQP2 reverses high levels of pentamidine
and melarsoprol resistance
We used the laboratory-generated cell line B4816 and its derivative
P1000 to investigate whether expression of wild-type (WT) TbAQP2
can fully reverse the multidrug resistance phenotype of these
clones. P1000 was developed by further adaptation of B48 to
1 mM pentamidine in vitro and thus its resistance phenotype is
believed to be multifactorial; B48 itself was derived from the
tbat12/2 strain and additionally lacks HAPT1 activity.16 Figure 1
shows the resistance profile of WT s427 and of B48 and P1000
transfected with the empty vector (EV) pHD1336 and with the
same vector containing WT TbAQP2.37 The lipophilic arsenical
PAO was used as a control as it has been shown to diffuse across
the T. b. brucei plasma membrane,16 making its action
Table 1. Overview of trypanosome strains used in this study
Strain Subspecies
Susceptibilitya
Adapted from Resistance induction
Infectivity Transport activity
Referencespentamidine arsenical rodents tsetse P2 HAPT1 LAPT1
Lister 427 T. b. brucei +++ +++ NA NA p pb p p p 14,16,17
2T1 T. b. brucei +++ +++ Lister 427 NA unkn unkn p p p 31,20
aqp2/aqp3 null T. b. brucei +/2 + 2T1 NA unkn unkn p NP p 20
TbAT1-KO T. b. brucei ++ ++ Lister 427 TGD p unkn NP p p 14
B48 T. b. brucei 2 +/2 TbAT1-KO in vitro, pentamidine p unkn NP NP p 16
P1000 T. b. brucei 222 +/2 B48 in vitro, pentamidine unkn unkn NP NP p —
STIB 247 T. b. brucei +++ +++ NA NA p p p p p 33,57,52
STIB 247MR T. b. brucei +/2 2 STIB 247 in vivo, Cymelarsan p p NP NP p 33,57,52
STIB 386 T. b. gambiense +++ ++ NA NA p p p p p 33,57,52
STIB 386MR T. b. gambiense +/2 2 STIB 386 in vivo, Cymelarsan p p NP NP p 33,57,52
STIB 900 T. b. rhodesiense +++ +++ NA NA p unkn p unkn unkn 56
STIB 900-M T. b. rhodesiense 2 2 STIB 900 in vitro, Cymelarsan
p
unkn NP unkn unkn 56
STIB 900-P T. b. rhodesiense 2 +/2 STIB 900 in vitro, pentamidine p unkn mutc unkn unkn 56
p
, present; NP, not present; NA, not applicable; unkn, unknown; TGD, targeted gene deletion of the TbAT1 gene creating a tbat1null line; MRor -M, resistance
induced to melaminophenyl arsenicals (melarsoprol and/or Cymelarsan); -P, resistance induced to pentamidine.
aSusceptibility to pentamidine or arsenical drugs is indicated on a relative scale as highly sensitive (+++) ranging to highly resistant to pentamidine or
melaminophenyl arsenicals (222).
bThe clone used in this paper is not tsetse transmissible but other clones of s427 have been shown to infect tsetse flies.34
cBernhard et al.56 reported that STIB 900-P contained a wild-type TbAT1 gene; later analysis revealed that in fact the TbAT1 open reading frame contains
one coding mutation (G1288C, leading to Gly430Arg).
Table 2. Kinetic parameters of high-affinity and low-affinity pentamidine transport in 247 and 386 procyclics
Pentamidine
Propamidine
Pentamidine
HAPT1 Km (mM) HAPT1 Vmax (pmol/10
7 cells/s) HAPT1 Ki (mM) LAPT1 Km (mM) LAPT1 Vmax (pmol/10
7 cells/s)
STIB 247WT 0.029+0.001 0.008+0.002 14+2 49+19 0.65+0.17
STIB 247MR NP 56+19 0.41+0.10
STIB 386WT 0.027+0.004 0.007+0.002 22+6 46+9 0.70+0.15
STIB 386MR NP 51+2 1.2+0.4
Uptake of [3H]pentamidine by suspensions of 107 procyclic trypanosomes was measured at 25 nM or 1 mM for the determination of parameters of
high-affinity transport (HAPT1 mediated) or low-affinity transport (LAPT1 mediated), respectively. In the 247MR and 386MR strains, no high-affinity
pentamidine transport was observed and transport rates were very low, with saturation only at very high concentrations of unlabelled pentamidine,
consistent with uptake by LAPT1. NP, not present in these cells.
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independent of transporters and showing that the resistance
phenotype is not to arsenic per se.
The EV controls B48 and P1000 were strongly resistant to the
diamidines pentamidine and diminazene as well as to the MPA
drug Cymelarsan, but not to PAO. Expression of TbAQP2 in B48
and P1000 completely reversed resistance to pentamidine
(50- and 240-fold, respectively) and Cymelarsan (16.7- and
15.0-fold, respectively) in both resistant clones (Figure 1).
However, the level of diminazene resistance in these lines was
not affected, consistent with the lack of diminazene resistance
in an aqp2 null line.20
A chimeric AQP2/3 gene in the AQP2 locus of B48 and
P1000 is distributed over the cell surface and does not
affect pentamidine and arsenic sensitivity
In B48, the AQP2 locus has been replaced by a chimeric in-frame
fusion of AQP2 and AQP3 (chAQP2/3) whereas AQP3 has remained
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unchanged.20 An identical chAQP2/3 and AQP3 locus was found in
P1000, showing that the higher level of pentamidine resistance in
P1000 was not due to further changes to the AQP2-AQP3 locus.
The observation that expression of WT AQP2 reverses the B48
and P1000 MPXR phenotypes (Figure 1) suggests that chAQP2/3
coincides with the loss of AQP2 function. This was further investi-
gated by expressing either WT AQP2 or chAQP2/3 in the aqp2 null
line produced from this strain.20 Expression of WT AQP2 reversed
the aqp2 null phenotype, whereas expression of chAQP2/3 had
much less effect on sensitivity to any of the drugs tested (Figure 2).
This confirms that the chimeric form does not function like AQP2,
at least with respect to pentamidine susceptibility (P.0.05),
whether it still exercises an AQP-like activity or not. We did observe
a small but significant (1.4-fold; P,0.05) difference in Cymelarsan
susceptibility between theaqp2null clone and the same cells expres-
sing chAQP2/3, although the effect was very much smaller than the
expression of WTAQP2 (4.1-fold; P,0.001). The (over)expression of
WT AQP2 in an aqp2 null or aqp2/aqp3 double-null background
appeared to make the cells slightly less susceptible to diminazene,
the reverse of its effect on pentamidine and Cymelarsan sensitivity.
There were no significant differences between any of the lines with
respect to PAO. Expression of AQP2 in the WT trypanosomes did
not elicit any change in drug susceptibility (Figure 2).
Apart from the primary sequence differences between TbAQP2
and TbAQP3, their cellular location is also different, with AQP2
restricted to the flagellar pocket whereas AQP3 is present through-
out the plasma membrane.20 As this could have bearing on the
MPXR phenotype, a fusion gene of chAQP2/3 N-terminally coupled
to GFP was constructed and introduced into the aqp2/aqp3 null
strain. Expression of the fusion protein was confirmed by western
blotting (Figure 3a). The localization in trypanosomes was observed
directlybyfluorescencemicroscopy. ItwasfoundthattheGFP-tagged
chAQP2/3, unlike AQP2, was present on the plasma membrane
(Figure 3b).
Expression of WT TbAQP2 correlates with the HAPT1
pentamidine transport activity
The strong phenotype of pentamidine resistance in aqp2 null lines
(16.3-fold;n¼22;P,0.001) prompted us to investigate the uptake
of [3H]pentamidine in these cells and compare this with that in the
parental 2T1 cells. We chose a [3H]pentamidine concentration of
30 nM in the presence of 1 mM adenosine; this concentration of ad-
enosine fully blocks the P2 aminopurine transporter53 and the
30 nMlabelconcentrationproducesabiphasicuptakethatvisualizes
uptake through both high- and low-affinity pentamidine transpor-
ters (HAPT1 and LAPT1).16 Propamidine was used as a specific inhibi-
tor of HAPT1, having no effect on LAPT1 activity.17 In four
independent experiments in triplicate, [3H]pentamidine uptake
was assessed, in parallel, in WTand in aqp2 null cells.
As expected in control trypanosomes, inhibition of the uptake of
[3H]pentamidine with unlabelled pentamidine in the range 10 nM–
1 mM produced a biphasic curve, of which only the first (high-
affinity) phase was sensitive to inhibition by propamidine
(IC50¼29.9+4.3 mM; n¼3). Plotting the pentamidine inhibition
data to an equation for a biphasic sigmoidal curve (two-site inhib-
ition; GraphPad Prism 5.0) yielded mean IC50 values that were
entirely compatible with the HAPT1/LAPT1 system: 0.060+0.017
and 29.9+4.3 mM (n¼3), respectively (Figure 4). In the aqp2 null
cells, [3H]pentamidine uptake was much lower, completely
lacked the high-affinity inhibition phase with unlabelled pentami-
dine and was insensitive to propamidine (Figure 4). The mean
IC50 value of 33.4+9.5 mM was statistically identical to the lower-
affinity phase of the WT 2T1 cells and with the published pentami-
dine Km for LAPT1 (56.2+8.3 mM).
17 We conclude that aqp2 null
cells do not express HAPT1, but do express LAPT1.
We previously reported that the pentamidine-resistant clone
B48 similarly lacks HAPT1 pentamidine transport activity as a
result of in vitro resistance selection with pentamidine16 and that
this clonal line lacks a WT AQP2 gene.20 We therefore tested
whether introduction of wild-type TbAQP2, in addition to restoring
pentamidine susceptibility (Figure 1), would reinstate HAPT1
activity. Figure 5 shows the rates of uptake at [3H]pentamidine
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Figure 4. Uptake of 30 nM [3H]pentamidine by aqp2 null and wild-type
control cells. Cells of T. b. brucei strain 2T1 (closed symbols) or the derived
aqp2 null strain (open symbols) were incubated with [3H]pentamidine for
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pentamidine (circles) or propamidine (squares). The incubation was stop-
ped by the addition of 1 mL ice-cold 1 mM pentamidine and immediate
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Figure 3. Localization of GFP-chAQP2/3 expressed in bloodstream-form
aqp2/aqp3 null trypanosomes. (a) Western blot using anti-GFP antiserum
as described previously.20 Blotting was performed after induction with
1 mg/mL tetracycline (+) or without induction as control (2). The
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localized to the plasma membrane. Blue colour is DAPI staining of
nucleus and kinetoplast. The scale bar represents 10 mm.
Munday et al.
656
concentrations that favour uptake by HAPT1 (50 nM; Figure 5a) or
LAPT1 (1 mM; Figure 5b); an s427-based cell line from which the
TbAT1/P2 transporter was removed by homologous recombination
(TbAT1-KO)14 was used as the control, as this was the strain B48
was derived from.16 Consistent with earlier findings, uptake of
50 nM [3H]pentamidine was reduced 15.5-fold in B48 compared
with in the TbAT1-KO control (P,0.001), whereas uptake of 1 mM
pentamidine was not significantly different. Expression of TbAQP2
in B48 increased uptake of 50 nM pentamidine 27.7-fold (P,0.02;
Figure 5a) to a level that appeared somewhat higher than that in
TbAT1-KO, although that difference did not reach statistical signifi-
cance. Uptake of 1 mM pentamidine was also increased upon intro-
duction of TbAQP2, but by only 2.5-fold (P,0.02; Figure 5b) and
again was not significantly different from the level in TbAT1-KO.
These data confirm that expression of TbAQP2 in B48 restores the
pentamidinetransportconditionsofTbAT1-KO, completely reversing
transport-related resistance.
We next investigated whether the increased pentamidine uptake
rates were indeed due to the expression of a HAPT1 activity in B48
cells re-expressing AQP2. Km and Vmax values of HAPT1 and LAPT1
were determined in B48/AQP2 (Figure 5c and d) and compared
with previously obtained values for WT s427, B48 and TbAT1-KO
(Table 3). No clear or significant differences were observed with the
kinetic parameters of pentamidine transport in bloodstream forms
of other s427-derived strains (WT s427, TbAT1-KO and B48), includ-
ing P1000, for which the pentamidineKm andVmax values (Figure S5;
available as Supplementary data at JAC Online) were also added to
Table 3. We conclude that expression of TbAQP2 reinstated a high-
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Figure 5. [3H]pentamidine uptake by various s427-derived trypanosome lines. (a) [3H]pentamidine concentration was 50 nM, reflecting predominantly
HAPT1-mediated uptake. (b) [3H]pentamidine concentration was 1 mM, reflecting predominantly LAPT1 uptake. Rates were determined from the
slopes of time courses over 10 min with timepoints at 0, 1, 3, 5, 7.5 and 10 min. Lines were linear, with none of the lines showing significant deviation
from linearity in a runs test (GraphPad Prism 5.0). Slopes of control time courses in the presence of 1 mM unlabelled pentamidine were all
non-significantly different from zero (F-test, GraphPad Prism 5.0), whereas uptake with unlabelled inhibitor was highly significantly different from zero
(typically P,0.0001). Results are the mean of three to four independent experiments, each performed in triplicate. (c, d) Uptake of [3H]pentamidine in
bloodstream forms of B48/AQP2 was determined as described in the legend to Figure 4. The experiments shown are representative of three
independently performed replicates. (c) Uptake of 30 nM [3H]pentamidine. (d) Uptake of 1 mM [3H]pentamidine. Solid squares, coincubation with
various concentrations of unlabelled pentamidine; open circles, coincubation with propamidine. **P, 0.01; ***P, 0.001.
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affinity pentamidine transport activity that is indistinguishable from
the well-characterized HAPT1, whilst making no detectable change
to the LAPT1 activity.
TbAQP2 displays HAPT1 activity when expressed
in L. mexicana
Leishmania spp. are relatively insusceptible to pentamidine and
tolerant to MPAs, as they lack high-affinity uptake systems for
these drugs. In order to investigatewhetherT. b. bruceiAQPs direct-
ly mediate uptake of these drugs, we expressed TbAQP2 and
TbAQP3 in promastigotes of L. mexicana. Comparisons of control
cells (transfected with EV) and cells expressing TbAQP2 showed
40-fold sensitization in two independent clones (Figure 6a) and a
.1000-fold sensitization to MPAs (Figure 6b). There was no statis-
tically significant effect on sensitivity to diminazene, relative to the
EV control (Figure 6c), or to amphotericin B (Figure 6d); the latter
was used as a control antileishmanial drug thought to bind to
plasma membrane ergosterol, therebyforming pores.54 Expression
of TbAQP3 in two independent clones led to minor (1.5–2.5-fold)
sensitization to pentamidine.
Consistent with this minor effect of AQP3 expression, uptake of
100 nM [3H]pentamidine in TbAQP3-transfected promastigotes
was not significantly different from that in the control when
measured over 5 min (Figure 7a and data not shown). In contrast,
pentamidine uptake in TbAQP2-expressing cells was increased
almost 15-fold (Figure 7a). Indeed, uptake of very low con-
centrations of [3H]pentamidine (50 nM) was measurable in
TbAQP2-expressing promastigotes within 3 s, was linear with a
rate of 0.032+0.002 pmol/107 cells/s and completely saturable
with excess unlabelled pentamidine (Figure 7b). Competition with
unlabelled pentamidine, propamidine and diminazene was dose
dependent (Figure 7c) and followed Michaelis–Menten kinetics
(Figure 7d). Mean Km and Ki values for these inhibitors are listed
in Table 3 and show a kinetic profile entirely consistent with the
T. b. brucei HAPT1 activity, with an apparent Km value of
55+4 nM (n¼5).
TbAQP2 does not affect the activity of the P2 transporter
It has long been established that the P2 transport activity, encoded
by TbAT1, is an important determinant of diamidine and arsenical
Table 3. Kinetic parameters of high-affinity and low-affinity pentamidine transport in various strains of T. b. brucei bloodstream forms and in
Leishmania mexicana expressing TbAQP2
Strain HAPT1 pentamidine Km (mM) HAPT1 propamidine Ki (mM) HAPT1 diminazene Ki (mM) LAPT1 pentamidine Km (mM)
WT s427a 0.036+0.006 4.6+0.7 63+3 56+8
TbAT1-KOb 0.029+0.008 13.0+3.0 ND 50+17
B48c NP 56+7
P1000 NP 99+24
B48/AQP2 0.046+0.014 15.2+1.6 ND 66+1
L. mexicana/TbAQP2 0.055+0.004 8.1+0.8 100+21 not present in these cells
ND, not determined; NP, not present in these cells.
In the B48 and P1000 strains, no high-affinity transport of pentamidine was detectable, nor was pentamidine uptake inhibited by propamidine.
aDe Koning.17
bMatovu et al.14
cBridges et al.16
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Figure 6. Effect of expression of T. brucei aquaporins on drug susceptibility
of Leishmania mexicana. TbAQP2 and TbAQP3 were expressed in
promastigotes using the pNUS vector. Two independent clones of each
resulting cell line and the promastigotes transfected with the ‘empty’
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Tukey’s correction (GraphPad Prism 5.0). EV, empty-vector control.
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sensitivity in T. brucei.8,12 It is thus important to establish whether
the TbAQP2/HAPT1 activity has anyeffect on P2 activity. It has been
previously reported that the expression of P2 can be assessed
through susceptibility to some adenosine analogues.55 Indeed,
we found that susceptibility to tubercidin (7-deazaadenosine)
decreased 10-fold in the tbat12/2 strain (EC50¼2.65+0.23 mM) rela-
tive to s427 WT (0.23+0.03 mM; P,0.001; Student’s t-test). Similar-
ly, susceptibility to tubercidin, cordycepin (3′-deoxyadenosine) and
5′-deoxyadenosine increased .20-fold when TbAT1 was expressed
in the tbat12/2 strain B48 (P,0.001) (Figure S6; available as Supple-
mentary data at JAC Online), confirming susceptibility to cytotoxic
adenosine analogues as a sensitive indicator for TbAT1 expression
levels. However, the susceptibility of 2T1 WT and aqp2 null cells to
these same adenosine analogues was identical, as was the suscep-
tibility of B48+TbAQP2 versus control B48 cells (Figure S6, available
as Supplementary data at JACOnline). Susceptibility to pentamidine,
used as a positive control, was highly dependent on the expression of
TbAQP2 and/or TbAT1. We conclude that TbAQP2 does not regulate
P2 activity and is not itself a conduit for cytotoxic nucleosides.
Investigation of the TbAQP2 and TbAQP3 selectivity filters
as the determinant for MPXR
The TbAQP2 region that was replaced with the corresponding
TbAQP3 sequence in the recombination event that generated
chAQP2/3 contains most of the selectivity filter that is believed to
determine the distinct permeation profiles of AQPs.20 As the chi-
meric AQPs found in B48 and 247MR did not appear to have the
TbAQP2 functionality with respect to pentamidine and melarsoprol
susceptibility, we investigated whether MPXR is determined princi-
pally by the few amino acids of the selectivity filter. We used syn-
thetic genes of chAQP2/3 and of TbAQP3 with a TbAQP2
selectivity filter (chAQP2/3sf2 and AQP3sf2, respectively; alignment
in Figure S7, available as Supplementary data at JACOnline). These
were expressed in the aqp2/aqp3 null cell line. Analysis of the drug
susceptibility phenotype for the resultant lines showed that the
transplantation of the amino acid residues of the AQP2 selectivity
filter did not result in an AQP2 phenotype with respect to drug sus-
ceptibility; therewas onlya minor increase in susceptibilityand only
to pentamidine (EC50 values of 158+2 and 131+3 nM, P,0.02,
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Figure 7. Expression of T. b. brucei aquaporins in promastigotes of Leishmania mexicana. (a) Specific uptake of 100 nM [3H]pentamidine over 5 min in
L. mexicana promastigotes transfected with empty pNUS vector (control), or promastigotes transfected with TbAQP2 or with TbAQP3. In each case,
mediated uptake of 100 nM radiolabel was compared with total association of [3H]pentamidine with the cell pellet in the presence of a saturating
concentration (1 mM) of unlabelled pentamidine. The data shown are the mean of triplicates+SEM. ***P,0.001 by one-way ANOVA, compared with
all other datasets. (b) Time course of 50 nM [3H]pentamidine uptake, over 15 s, using L. mexicana promastigotes transformed with TbAQP2 in the
presence and absence of 1 mM unlabelled pentamidine. Uptake at 50 nM pentamidine was linear (r2¼0.98) and rapid (0.032+0.002 pmol/107 cells/s,
compared with 0.00026+1.8×1026 pmol/107 cells/s in the presence of 1 mM pentamidine). (c) Characterization of 20 nM [3H]pentamidine uptake in
L. mexicana promastigotes expressing TbAQP2, in the presence of varying concentrations of unlabelled inhibitor. (d) Michaelis–Menten plot of 20 nM
[3H]pentamidine uptake; conversion of pentamidine inhibition plot in (c).
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for aqp2/aqp3 null and AQP3sf2, respectively; Figure 8). In contrast,
the cell line expressing the chAQP2/3sf2 construct was significantly
more susceptible to Cymelarsan than the aqp2/aqp3 null back-
ground, reaching susceptibility to this drug halfway between the
aqp2/aqp3 null and the same line expressing WT AQP2 (Figure 8).
These findings indicate that the selectivity filter residues do play
a role in arsenical drug sensitivity, but that the changes described
here were insufficient to produce the same effect as WT AQP2 on
pentamidine susceptibility.
Discussion
Although we recently reported that the absence of a wild-typeAQP2
gene correlates with MPXR in T. b. brucei,20 many important ques-
tions remained. It remained unclear (i) whether this phenomenon
is relevant for human-infective trypanosome subspecies, (ii)
whether loss of AQP2 occurs as a result of in vivo drug exposure,
(iii) whether loss of AQP2 alone is sufficient for high levels of pent-
amidine and melarsoprol resistance, (iv) by which mechanism
AQP2 facilitated pentamidine and melarsoprol sensitivity and (v)
whether AQP2 has any impact on TbAT1/P2 activity. We now
provide answers to these questions.
Only TbAQP2 was implicated in MPXR, with the expression of
TbAQP3 in an aqp2/aqp3 null line having no effect on drug suscep-
tibility.20 This is most likely the result of differences in permeation,
as all three TbAQPs are located on the cell surface, although AQP2
was found to be restricted to the flagellar pocket rather than dis-
persed over the plasma membrane.20,28 Interestingly, a chimeric
AQP, made up from TbAQP2 and TbAQP3 (chAQP2/3) was present
instead of wild-type TbAQP2 in the highly MPXR strain T. b. brucei
B48, which retained a wild-type copyofTbAQP3 found in the paren-
tal, drug-susceptible strain.20 Here, we report that in other isogenic
MPXR pairs, the adapted strain similarly showed a replacement of
TbAQP2 with a different chimeric AQP2/3 fusion or an outright de-
letion of TbAQP2. This was the case whether the strain was origin-
ally adapted to pentamidine or to an MPA drug, whether the
subspecies was T. b. brucei, T. b. gambiense or T. b. rhodesiense
and for strains that were selected by either in vivo or in vitro drug
pressure. It thus follows that for T. brucei subspecies, loss of
TbAQP2 function represents an important component of acquiring
high levels of resistance to MPAs and that this necessarily leads to
pentamidine resistance as well, and vice versa. We also conclude
that loss of AQP2 can be the result of in vivo drug pressure and
that this does not significantly affect virulence and does not
impede transmission by tsetse flies, as STIB 386MR and STIB
247MR produce similar parasitaemias in mice compared with the
wild-type lines from which they were derived and were fly trans-
missible.33
One important question is whether loss of TbAQP2 alone is suf-
ficient for MPXR in vivo. Certainly, the deletion of just TbAQP2 ren-
dered a highly drug-susceptible T. b. brucei strain resistant to
pentamidine (but not diminazene) and Cymelarsan (but not PAO)
in vitro;20 this shows that the resistance is not to all aromatic dia-
midines or to arsenic per se. Similarly, the reintroduction of wild-
type TbAQP2 into B48 or P1000 restored sensitivity to Cymelarsan
and pentamidine (but not diminazene) to wild-type levels. Both
strains retained their diminazene resistance, which is linked to
the loss of the TbAT1/P2 transporter,14,50 which is absent in B48
1 2 3 4 5
0
3
6
20
70
120
170 ** **
***
***
EC
50
 (n
M
)
1 2 3 4 5
0
10
20
30
40
50
***
******
**
EC
50
 (n
M
)
1 2 3 4 5
0
40
80
120
EC
50
 (n
M
)
1 2 3 4 5
0.0
0.5
1.0
1.5
2.0
2.5
3.0
EC
50
 (n
M
)
(a)
(c) (d)
(b)
1.  aqp2/aqp3 null
2.  aqp2/aqp3 null with AQP3sf2
3.  aqp2/aqp3 null with AQP2/3sf2
4.  aqp2/aqp3 null with WT AQP2
5.  2T1 WT
Figure 8. Expression of synthetic aquaporin constructs in bloodstream forms of the aqp2/aqp3 double-null line. EC50 values were determined for (a)
pentamidine, (b) Cymelarsan, (c) diminazene and (d) phenylarsine oxide. Expression was induced by the addition of 1 mg/mL tetracycline 24 h before
setting up the plates for the assay, followed by 48 h of incubation of the cells in the presence of a doubling dilution of the test compound followed by a
further 24 h of incubation with the dye before fluorescence was determined. All data are the mean of at least three independent determinations; error
bars are SEM. Statistical significance with aqp2/aqp3 null was determined using a one-way ANOVA with Tukey’s correction (GraphPad Prism 5.0);
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and P1000 cells.16 Indeed, TbAT1 is absent or mutated in all the
drug-adapted MPXR strains used here,56,57 opening up the possibil-
ity that both transport activities must be absent for high levels of
MPXR. It has already been established that homozygous deletion
of TbAT1 alone results in a relatively minor (2.5–3-fold) loss of sen-
sitivity to pentamidine and MPAs;14 a similar level of MPA resistance
was observed in the aqp2 null and aqp2/aqp3 null lines, which do
retain a wild-type copy of TbAT1. Although the data presented
here and by Baker et al.20 show that the deletion of TbAQP2 alone
is sufficient to give a strong pentamidine resistance phenotype in
vitro (17.5-fold; Figure 2), it is worth exploring this in detail. Firstly,
TbAT1/P2 activity is very low in cultured T. b. brucei bloodstream
forms, compared with expression in vivo,15 dramatically reducing
the influence of this transporter on drug sensitivity. Secondly,
the pHD1336 vector used to reintroduce TbAQP2 in B48 and
P1000 gives a very robust expression level,37 well above that
in the wild-type, which helps explain the complete reversal of
MPA/pentamidine resistance even in the absence of TbAT1.
Finally, the reintroduction of TbAT1 in B48 in the same vector also
led to an almost complete reversal of resistance to pentamidine,
Cymelarsan and diminazene, even in the continued absence of a
wild-type TbAQP2.58
The conclusion from the above must be that loss of either
TbAQP2 or TbAT1 activity can lead to some loss of MPA and pent-
amidine susceptibility, but that the high MPXR phenotype is the
result of both being lost concomitantly. B48, which lacks both
genes, is more resistant to pentamidine and MPAs than either
aqp2 null or the TbAT1 knockout strain from which it was derived.
Thus, the combined data strongly suggest that TbAQP2 is the
previously described HAPT1 and transports MPAs and pentamidine.
A number of observations reported in the present article strongly
support this notion: (i) the T. b. brucei strains B48, P1000 and
247MR and T. b. gambiense 386MR have all lost HAPT1 activity
and also lack a wild-type copy of TbAQP2; (ii) targeted deletion of
TbAQP2 specifically removes the high-affinity pentamidine trans-
port component, leaving the low-affinity transport activity un-
changed; (iii) expression of TbAQP2 in B48 restores HAPT1 activity;
(iv) expression of TbAQP2 in L. mexicana causes a massive sensitiza-
tion to pentamidine and Cymelarsan; and (v) the introduction of a
high-affinity pentamidine transporter that is indistinguishable from
HAPT1 by Km value and inhibitor profile. Thus, the evidence over-
whelmingly supports a model that TbAQP2 mediates the saturable
uptake of pentamidine and MPAs, following standard Michaelis–
Menten kinetics, in addition to its more conventional function as a
water/glycerol channel.
As discussed by Baker et al.,20 TbAQP2 has a number of unusual
residues in the motifs that are believed to be involved in selectivity:
NPS/IVLL is replaced with the classical regions of NPA/IGYR in the
chimera. To begin to unravel the structural determinants of AQP2
action, we synthesized two new genes, with the NPS/IVLL motif
transplanted to either chAQP2/3 or TbAQP3, and expressed these
constructs in an aqp2/aqp3 null strain. The resulting cell lines dis-
played slightly higher pentamidine sensitivity than the control
and the cells expressing chAQP2/3sf2 showed a substantial sensi-
tization to Cymelarsan. It follows that the usual selectivity filter
of TbAQP2 does indeed contribute to its drug transport capacity,
but is not the sole determinant.
In summary, we have shown that an aquaglyceroporin, TbAQP2,
mediates the saturable uptake of some first-line trypanocides, Cym-
elarsan and pentamidine, compounds of substantially higher
molecular weight than has so far been reported for any AQP.
The mechanism by which this MIP transports these drugs with
Michaelis–Menten kinetics remains to be investigated.
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